Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Researchers discover control mechanism that can trigger development of MDS

Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes (MDS), a group of blood cancers. This finding may lead to therapies capable of preventing the progression of these diseases.

17 Dec 2013

Illinois healthcare coalition receives $7M grant to establish research network to battle chronic illnesses

Governor Quinn today announced that a coalition of 20 health and hospital organizations from Illinois has been awarded an 18-month, $7million federal award to establish a clinical data research network.

17 Dec 2013

Blending more ethanol into fuel to reduce air pollution carries hidden risk

Blending more ethanol into fuel to cut air pollution from vehicles carries a hidden risk that toxic or even explosive gases may find their way into buildings, according to researchers at Rice University.

15 Dec 2013

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

Two tumor-suppressing genes could play vital role in controlling obesity, cancer, diabetes

The function of two tumor-suppressing genes could play a vital role in helping to control obesity and other diseases such as diabetes, heart disease and cancer, according to researchers in Temple University's Sbarro Institute for Cancer Research and Molecular Medicine.

12 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Acid-inhibiting medications linked with increased risk for vitamin B12 deficiency

Use for 2 or more years of proton pump inhibitors and histamine 2 receptor antagonists (two types of acid-inhibiting medications) was associated with a subsequent new diagnosis of vitamin B12 deficiency, according to a study appearing in the December 11 issue of JAMA.

11 Dec 2013

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Genzyme granted Priority Review for Cerdelga investigational oral therapy for Gaucher disease

Genzyme, a Sanofi company, announced today that the Food and Drug Administration (FDA) has granted a six-month Priority Review designation to its New Drug Application (NDA) for Cerdelga™ (eliglustat), an investigational oral therapy for adult patients with Gaucher disease type 1.

11 Dec 2013

Immunologists receive $4.8M grant to target multiple diseases by manipulating enzyme

Immunologists Barbara A. Osborne and Lisa M. Minter at the University of Massachusetts Amherst, as part of a multi-institution research team, will share a five-year, $4.8 million National Cancer Institute grant to target multiple diseases including cancer, Alzheimer's and graft-versus-host disease (GVHD) by manipulating an enzyme that activates over 100 different protein substrates in the body.

10 Dec 2013

Study links vitamin B12 deficiency to acid-suppressing medications

Long-term use of commonly prescribed heartburn and ulcer medications is linked to a higher risk of vitamin B12 deficiency, according to a new study published online in the Journal of the American Medical Association.

10 Dec 2013

Pemetrexed, paclitaxel regimens equally effective in NSCLC

PointBreak trial results suggest that pemetrexed- and paclitaxel-based chemotherapy offer comparable survival outcomes and tolerability for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) but with differing toxicity profiles.

10 Dec 2013

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops targeted, antibody-based anticancer therapeutics, today announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy.

10 Dec 2013

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013.

9 Dec 2013

Ligand announces data from preclinical studies on small-molecule oral G-CSF receptor agonist

Ligand Pharmaceuticals Incorporated announced that data from preclinical studies on its granulocyte colony stimulating factor (G-CSF) receptor agonist program were featured in a poster presentation today at the 55th Annual Meeting of the American Society of Hematology in New Orleans.

9 Dec 2013

Scientists recommend testing for Pearson syndrome in patients with congenital anemia

Some babies diagnosed with and treated for a bone marrow failure disorder, called Diamond Blackfan Anemia, may actually be affected by a very rare anemia syndrome that has a different disease course and treatment, say scientists from Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

8 Dec 2013

Researchers produce erythrocyte progenitor cells by transducing two genes into iPS and ES cells

By transducing two genes (c-MYC and BCL-XL) into iPS cells and ES cells, a Kyoto University research team led by Prof. Koji Eto at CiRA has succeeded in producing erythrocyte progenitor cells with almost unlimited ability to replicate in vitro, which they then differentiated successfully into mature erythrocytes. Although these erythrocytes consisted mostly of fetal-type hemoglobin, they were confirmed to have oxygen-carrying capacity and to have circulatory capacity following transfusion into mice.

6 Dec 2013

Telomerase inhibiting drug induces morphologic, molecular, clinical remissions in myelofibrosis patients

metelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis a Mayo Clinic study has found. The results were presented today at the 2013 American Society of Hematology Annual Meeting in New Orleans.

6 Dec 2013

Ligand revises previous revenue and net income guidance for fourth quarter and full year 2013

Ligand Pharmaceuticals Incorporated is revising upward its previous revenue and net income guidance for the fourth quarter and full year 2013 as a result of higher-than-expected sales of Captisol® material.

4 Dec 2013

Anemia News and Research

Further Reading

Researchers discover control mechanism that can trigger development of MDS

Illinois healthcare coalition receives $7M grant to establish research network to battle chronic illnesses

Blending more ethanol into fuel to reduce air pollution carries hidden risk

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Two tumor-suppressing genes could play vital role in controlling obesity, cancer, diabetes

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Acid-inhibiting medications linked with increased risk for vitamin B12 deficiency

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Genzyme granted Priority Review for Cerdelga investigational oral therapy for Gaucher disease

Immunologists receive $4.8M grant to target multiple diseases by manipulating enzyme

Study links vitamin B12 deficiency to acid-suppressing medications

Pemetrexed, paclitaxel regimens equally effective in NSCLC

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

Ligand announces data from preclinical studies on small-molecule oral G-CSF receptor agonist

Scientists recommend testing for Pearson syndrome in patients with congenital anemia

Researchers produce erythrocyte progenitor cells by transducing two genes into iPS and ES cells

Telomerase inhibiting drug induces morphologic, molecular, clinical remissions in myelofibrosis patients

Ligand revises previous revenue and net income guidance for fourth quarter and full year 2013

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News